Статті в журналах з теми "APR-246"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "APR-246".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Jonsson-Videsater, Kerstin, Dina Ali, Hareth Nahi, Sofia Bengtzen, Stefan Deneberg, Christer Paul, and Soren Lehmann. "In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs." Blood 114, no. 22 (November 20, 2009): 2751. http://dx.doi.org/10.1182/blood.v114.22.2751.2751.
Повний текст джерелаCeder, Anna Sophia, Sofi E. Eriksson, Emarndeena Haji Cheteh, Vladimir J. N. Bykov, Lars Abrahmsen, and Klas G. Wiman. "Impact of combined MRP1 inhibition and mutant p53-targeting compound APR-246." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e14712-e14712. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14712.
Повний текст джерелаMüller, Michael, Lisa Rösch, Sara Najafi, Charlotte Gatzweiler, Johannes Ridinger, Xenia F. Gerloff, David T. W. Jones, et al. "Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma." Cancers 13, no. 17 (September 5, 2021): 4476. http://dx.doi.org/10.3390/cancers13174476.
Повний текст джерелаHong, Yuheng, Tianyuan Ren, Xiaoxuan Wang, Kai Fu, Xianhuo Wang, and Huilai Zhang. "APR-246 Reveals a Therapeutic Potential Via Triggering Different Cell Death Mechanisms in Diffuse Large B Cell Lymphoma." Blood 138, Supplement 1 (November 5, 2021): 3521. http://dx.doi.org/10.1182/blood-2021-150582.
Повний текст джерелаSynnott, Naoise C., Alyson M. Murray, Norma O'Donovan, Michael J. Duffy, and John Crown. "Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e14098-e14098. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14098.
Повний текст джерелаXin, Qian, Qinghong Ji, Ying Zhang, Weihong Ma, Baoqing Tian, Yanli Liu, Yunsong Chen, et al. "Aberrant ROS Served as an Acquired Vulnerability of Cisplatin-Resistant Lung Cancer." Oxidative Medicine and Cellular Longevity 2022 (June 20, 2022): 1–17. http://dx.doi.org/10.1155/2022/1112987.
Повний текст джерелаMohell, Nina, Charlotta Liljebris, Jessica Alfredsson, Ylva Lindman, Maria Uustalu, Thomas Uhlin, Mats R. H. Linderholm, and Klas G. Wiman. "Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer." Blood 116, no. 21 (November 19, 2010): 1806. http://dx.doi.org/10.1182/blood.v116.21.1806.1806.
Повний текст джерелаVenkatesh, Divya, Judith Michels, Cailian Liu, Sadna Budhu, Mariam M. George, Lars Abrahmsen, Roberta Zappasodi, Jedd D. Wolchok, and Taha Merghoub. "Abstract 1291: APR-246 enhances tumor immunogenicity even in the absence of p53." Cancer Research 82, no. 12_Supplement (June 15, 2022): 1291. http://dx.doi.org/10.1158/1538-7445.am2022-1291.
Повний текст джерелаNagourney, Adam J., Joshua B. Gipoor, Steven S. Evans, Paulo D’Amora, Max S. Duesberg, Paula J. Bernard, Federico Francisco, and Robert A. Nagourney. "Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants." Genes 14, no. 3 (March 19, 2023): 747. http://dx.doi.org/10.3390/genes14030747.
Повний текст джерелаMacha, Shawn J., Balakrishna Koneru, Trevor Burrow, Charles Zhu, Dzmitry Savitski, Jonas Nance, Kristyn McCoy, Cody Eslinger, and C. Patrick Reynolds. "Abstract 6228: APR-246, which restores p53 function, is highly active against alternative lengthening of telomere (ALT) cell lines and PDXs." Cancer Research 82, no. 12_Supplement (June 15, 2022): 6228. http://dx.doi.org/10.1158/1538-7445.am2022-6228.
Повний текст джерелаLiang, Yayun, Rolf A. Brekken, and Salman M. Hyder. "Inhibiting Growth of Human Triple-Negative Breast Cancer Cells by Activating Mutant p53 Protein Alone or in Combination With a Phosphatidylserine-Targeting Antibody." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A1022—A1023. http://dx.doi.org/10.1210/jendso/bvab048.2093.
Повний текст джерелаMohell, Nina, Charlotta Liljebris, Jessica Alfredsson, Ylva Lindman, Maria Uustalu, Klas G. Wiman, and Thomas Uhlin. "Further Preclinical Studies with APR-246, a Novel Anticancer Compound Currently in Clinical Trials for Hematological Malignancies and Prostate Cancer." Blood 114, no. 22 (November 20, 2009): 3773. http://dx.doi.org/10.1182/blood.v114.22.3773.3773.
Повний текст джерелаDe Sousa, Carla. "Errata ao artigo “Impacto do Confinamento em Crianças e Adolescentes”, Publicado em Acta Med Port 2021 Apr;34(4):245-246." Acta Médica Portuguesa 34, no. 5 (May 2, 2021): 406. http://dx.doi.org/10.20344/amp.16383.
Повний текст джерелаBarutello, Giuseppina, Antonino Di Lorenzo, Alessandro Gasparetto, Chiara Galiazzi, Elisabetta Bolli, Laura Conti, and Federica Cavallo. "Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models." Biomedicines 10, no. 11 (November 8, 2022): 2843. http://dx.doi.org/10.3390/biomedicines10112843.
Повний текст джерелаDemir, Salih, Galina Selivanova, Eugen Tausch, Lisa Wiesmüller, Stephan Stilgenbauer, Geertruy Te Kronnie, Klaus-Michael Debatin, and Lüder Hinrich Meyer. "Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia." Blood 126, no. 23 (December 3, 2015): 903. http://dx.doi.org/10.1182/blood.v126.23.903.903.
Повний текст джерелаMakhale, Ashwini, Devathri Nanayakkara, Prahlad Raninga, Kum Kum Khanna, and Murugan Kalimutho. "CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer." International Journal of Molecular Sciences 22, no. 11 (May 28, 2021): 5782. http://dx.doi.org/10.3390/ijms22115782.
Повний текст джерелаAbrams, Stephen L., Przemysław Duda, Shaw M. Akula, Linda S. Steelman, Matilde L. Follo, Lucio Cocco, Stefano Ratti, et al. "Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53." Cells 11, no. 5 (February 24, 2022): 794. http://dx.doi.org/10.3390/cells11050794.
Повний текст джерелаDeben, Christophe, Vanessa Deschoolmeester, Jorrit De Waele, Julie Jacobs, Jolien Van den Bossche, An Wouters, Marc Peeters та ін. "Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress". Cancers 10, № 4 (21 квітня 2018): 126. http://dx.doi.org/10.3390/cancers10040126.
Повний текст джерелаThompson, Meghan C., Matthew S. Davids, Nitin Jain, Jacob D. Soumerai, Praveen Ramakrishnan Geethakumari, Amy Gubits, Denice Hickman, et al. "Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)." Blood 136, Supplement 1 (November 5, 2020): 15–16. http://dx.doi.org/10.1182/blood-2020-139022.
Повний текст джерелаGhosh, Arnab, Judith Michel, Divya Venkatesh, Riccardo Mezzadra, Lauren Dong, Fadi Samaan, Ricardo Gomez, et al. "Abstract 250: Activating canonical p53 functions in tumor-associated macrophages improves immune checkpoint blockade efficacy." Cancer Research 82, no. 12_Supplement (June 15, 2022): 250. http://dx.doi.org/10.1158/1538-7445.am2022-250.
Повний текст джерелаLehmann, Sören, Vladimir J. N. Bykov, Dina Ali, Ove Andrén, Honar Cherif, Ulf Tidefelt, Bertil Uggla, et al. "Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer." Journal of Clinical Oncology 30, no. 29 (October 10, 2012): 3633–39. http://dx.doi.org/10.1200/jco.2011.40.7783.
Повний текст джерелаNikolaev, Anatoly, John B. Fiveash, and Eddy S. Yang. "Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG." International Journal of Molecular Sciences 21, no. 2 (January 13, 2020): 490. http://dx.doi.org/10.3390/ijms21020490.
Повний текст джерелаSallman, David A., Amy E. DeZern, Guillermo Garcia-Manero, David P. Steensma, Gail J. Roboz, Mikkael A. Sekeres, Thomas Cluzeau, et al. "Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes." Journal of Clinical Oncology 39, no. 14 (May 10, 2021): 1584–94. http://dx.doi.org/10.1200/jco.20.02341.
Повний текст джерелаByskata, Karin, Monika Lukoseviciute, Filippo Tuti, Mark Zupancic, Ourania N. Kostopoulou, Stefan Holzhauser, and Tina Dalianis. "Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited." Cancers 15, no. 1 (December 23, 2022): 93. http://dx.doi.org/10.3390/cancers15010093.
Повний текст джерелаSallman, David A., Amy E. DeZern, David P. Steensma, Kendra L. Sweet, Thomas Cluzeau, Mikkael A. Sekeres, Guillermo Garcia-Manero, et al. "Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)." Blood 132, Supplement 1 (November 29, 2018): 3091. http://dx.doi.org/10.1182/blood-2018-99-119990.
Повний текст джерелаMohell, N., J. Alfredsson, Å. Fransson, M. Uustalu, S. Byström, J. Gullbo, A. Hallberg, V. J. N. Bykov, U. Björklund, and K. G. Wiman. "APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells." Cell Death & Disease 6, no. 6 (June 2015): e1794-e1794. http://dx.doi.org/10.1038/cddis.2015.143.
Повний текст джерелаLi, Jing, Cheng Li, Guoliang Wang, Zhen Liu, Pei Chen, Qichen Yang, Nuo Dong, Huping Wu, Zuguo Liu, and Wei Li. "APR-246/PRIMA-1MetInhibits and Reverses Squamous Metaplasia in Human Conjunctival Epithelium." Investigative Opthalmology & Visual Science 57, no. 2 (February 11, 2016): 444. http://dx.doi.org/10.1167/iovs.15-17519.
Повний текст джерелаAryee, D. N. T., S. Niedan, J. Ban, R. Schwentner, K. Muehlbacher, M. Kauer, R. Kofler, and H. Kovar. "Variability in functional p53 reactivation by PRIMA-1Met/APR-246 in Ewing sarcoma." British Journal of Cancer 109, no. 10 (October 15, 2013): 2696–704. http://dx.doi.org/10.1038/bjc.2013.635.
Повний текст джерелаKrayem, Mohammad, Fabrice Journe, Murielle Wiedig, Renato Morandini, Ahmad Najem, François Salès, Leon C. van Kempen, et al. "p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib." European Journal of Cancer 55 (March 2016): 98–110. http://dx.doi.org/10.1016/j.ejca.2015.12.002.
Повний текст джерелаSynnott, Naoise C., Patricia M. McGowan, Aisling Pierce, Maeve Kiely, Norma O'Donovan, John Crown, Patrick A. Kiely, and Michael J. Duffy. "PRIMA-1MET (APR-246): A novel targeted therapy for triple negative breast cancer?" Journal of Clinical Oncology 33, no. 15_suppl (May 20, 2015): e12072-e12072. http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e12072.
Повний текст джерелаLiljebris, C., N. Mohell, E. Olaisson, T. Uhlin, K. G. Wiman, and S. Lehmann. "APR-246, a new class anticancer compound in phase l/lla clinical trials." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): TPS183. http://dx.doi.org/10.1200/jco.2010.28.15_suppl.tps183.
Повний текст джерелаMagri, Jolanda, Alessandro Gasparetto, Laura Conti, Enzo Calautti, Chiara Cossu, Roberto Ruiu, Giuseppina Barutello, and Federica Cavallo. "Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies." Cells 10, no. 1 (January 8, 2021): 108. http://dx.doi.org/10.3390/cells10010108.
Повний текст джерелаMagri, Jolanda, Alessandro Gasparetto, Laura Conti, Enzo Calautti, Chiara Cossu, Roberto Ruiu, Giuseppina Barutello, and Federica Cavallo. "Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies." Cells 10, no. 1 (January 8, 2021): 108. http://dx.doi.org/10.3390/cells10010108.
Повний текст джерелаRökaeus, N., J. Shen, I. Eckhardt, V. J. N. Bykov, K. G. Wiman, and M. T. Wilhelm. "PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73." Oncogene 29, no. 49 (September 6, 2010): 6442–51. http://dx.doi.org/10.1038/onc.2010.382.
Повний текст джерелаDeneberg, S., H. Cherif, V. Lazarevic, P.-O. Andersson, M. von Euler, G. Juliusson, and S. Lehmann. "An open-label phase I dose-finding study of APR-246 in hematological malignancies." Blood Cancer Journal 6, no. 7 (July 2016): e447-e447. http://dx.doi.org/10.1038/bcj.2016.60.
Повний текст джерелаCluzeau, Thomas, Marie Sebert, Ramy Rahmé, Stefania Cuzzubbo, Anouk Walter-petrich, Jacqueline Lehmann che, Pierre Peterlin, et al. "APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)." Blood 134, Supplement_1 (November 13, 2019): 677. http://dx.doi.org/10.1182/blood-2019-125579.
Повний текст джерелаNagourney, Adam Jeremiah, Steven Scott Evans, Max Serge Duesberg, Paulo D'Amora, Paula J. Bernard, Eric Francisco, and Robert Alan Nagourney. "Drugging the undruggable-targeting P53: A comparative analysis of APR-246 and coti-2 in human tumor primary culture explants." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e15092-e15092. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e15092.
Повний текст джерелаNagourney, Adam Jeremiah, Steven Scott Evans, Max Serge Duesberg, Paulo D'Amora, Paula J. Bernard, Eric Francisco, and Robert Alan Nagourney. "Drugging the undruggable-targeting P53: A comparative analysis of APR-246 and coti-2 in human tumor primary culture explants." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e15092-e15092. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e15092.
Повний текст джерелаFang, Y., and C. K. Chang. "PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME." HemaSphere 6 (June 2022): 1792–93. http://dx.doi.org/10.1097/01.hs9.0000850504.79008.eb.
Повний текст джерелаHang, Wei, Zhi-Xian Yin, Gang Liu, Qinghua Zeng, Xiang-Feng Shen, Qian-Hui Sun, Dong-Dong Li, et al. "Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1." Oncogene 37, no. 25 (January 18, 2018): 3384–98. http://dx.doi.org/10.1038/s41388-017-0110-2.
Повний текст джерелаSynnott, Naoise C., Stephen F. Madden, Vladimir J. N. Bykov, John Crown, Klas G. Wiman, and Michael J. Duffy. "The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells." Translational Oncology 11, no. 6 (December 2018): 1343–49. http://dx.doi.org/10.1016/j.tranon.2018.08.009.
Повний текст джерелаLiu, David S. H., Matthew Read, Carleen Cullinane, Walid J. Azar, Christina M. Fennell, Karen G. Montgomery, Sue Haupt, et al. "APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma." Gut 64, no. 10 (July 17, 2015): 1506–16. http://dx.doi.org/10.1136/gutjnl-2015-309770.
Повний текст джерелаRoszkowska, Katarzyna A., Aleksandra Piecuch, Maria Sady, Zdzisław Gajewski, and Sylwia Flis. "Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches." International Journal of Molecular Sciences 23, no. 21 (October 31, 2022): 13287. http://dx.doi.org/10.3390/ijms232113287.
Повний текст джерелаPeng, X., M.-Q.-Z. Zhang, F. Conserva, G. Hosny, G. Selivanova, V. J. N. Bykov, E. S. J. Arnér, and K. G. Wiman. "APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase." Cell Death & Disease 4, no. 10 (October 2013): e881-e881. http://dx.doi.org/10.1038/cddis.2013.417.
Повний текст джерелаAli, Dina, Kerstin Jönsson-Videsäter, Stefan Deneberg, Sofia Bengtzén, Hareth Nahi, Christer Paul, and Sören Lehmann. "APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells." European Journal of Haematology 86, no. 3 (January 11, 2011): 206–15. http://dx.doi.org/10.1111/j.1600-0609.2010.01557.x.
Повний текст джерелаSaha, Manujendra N., Hua Jiang, Yijun Yang, Donna Reece, and Hong Chang. "PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa." Molecular Cancer Therapeutics 12, no. 11 (September 12, 2013): 2331–41. http://dx.doi.org/10.1158/1535-7163.mct-12-1166.
Повний текст джерелаLi, Xiao-Lan, Jianbiao Zhou, Zit-Liang Chan, Jing-Yuan Chooi, Zhi-Rong Chen, and Wee-Joo Chng. "PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms." Oncotarget 6, no. 34 (October 1, 2015): 36689–99. http://dx.doi.org/10.18632/oncotarget.5385.
Повний текст джерелаLyle, MS, PA-C, Lindsey. "ASH Highlights and Commentary: Myeloid Malignancies." Journal of the Advanced Practitioner in Oncology 13, no. 2 (March 1, 2022): 15–23. http://dx.doi.org/10.6004/jadpro.2022.13.2.11.
Повний текст джерелаSeipel, Katja, Basil Kopp, Ulrike Bacher, and Thomas Pabst. "BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia." Cancers 13, no. 3 (February 2, 2021): 581. http://dx.doi.org/10.3390/cancers13030581.
Повний текст джерелаDe La Rosa, Javier, Alejandro Urdiciain, María Zelaya, Idoya Zazpe, Bárbara Meléndez, Juan Rey, Miguel Idoate, et al. "APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells." International Journal of Oncology 58, no. 3 (January 26, 2021): 312–30. http://dx.doi.org/10.3892/ijo.2021.5177.
Повний текст джерела